What is GLP-1 & How Does It Reduce Appetite & Promote Weight Loss? | Dr. Andrew Huberman
A short solo clip in which Huberman describes a Cell paper on GLP-1 and appetite, and the idea of parallel pathways, plus his comments on yerba mate.
Key moments
Tap a moment to play the video from there.
- 0:04A Cell paper on appetiteHuberman introduces a recent paper he says appeared in Cell and explains why he considers that journal prestigious.
- 0:34Defining parallel pathwaysHe describes parallel pathways as independent neural or hormonal routes serving one goal, and names GLP-1 as the peptide of interest.
- 1:04Yerba mate and new drugsHuberman says yerba mate can promote GLP-1 release and mentions new prescription drugs that stimulate GLP-1 or act as synthetic versions of it.
- 1:35What GLP-1 is said to doHe calls GLP-1 a small protein that can strongly suppress appetite, and says the drugs are being explored for type two diabetes and obesity.
- 2:06Caveats on smoked yerba mateHuberman says he avoids smoked varieties because of a potential carcinogenic concern, and likes yerba mate as an early-day caffeine source.
- 2:36Two mechanisms in the paperHe says the paper shows GLP-1 acting on enteric nervous system neurons, which he describes as an automatic part of the nervous system.
- 3:08Gut distension and fullnessHuberman says these neurons cause gut distension that makes people feel full, and expects mild rather than major distension at yerba mate-level doses.
- 4:09The gut to hypothalamus routeHe describes a pathway from the gut to the hypothalamus that he says also triggers satiety through brain mechanisms.
- 5:11Yerba mate for mild suppressionHuberman suggests yerba mate might suit people wanting mild appetite suppression alongside caffeine.
- 5:41Parallel pathways more broadlyHe gives adrenaline release from the adrenals and the locus coeruleus as another example, and says brain and body communication is typically bidirectional.
What the video says
This is a clip of about seven minutes in which Andrew Huberman talks through a recent paper he says was published in the journal Cell. He frames it as separate from the mental health topics he covers elsewhere. He uses it to introduce what he calls parallel pathways, meaning neural or hormonal routes that work independently of one another toward a common goal.
The peptide at the center is GLP-1, glucagon-like peptide one. Huberman describes it as a small protein that he says can strongly suppress appetite. He says a new category of prescription drugs, which either stimulate its release or are synthetic versions of it, has shown impressive clinical trial results for diabetes and obesity, and he describes them as leading to weight loss. He also says yerba mate can promote GLP-1 release, though in a much lower amount than such drugs. He adds that he personally avoids smoked varieties of yerba mate because of a possible carcinogenic concern.
According to Huberman, the paper shows GLP-1 suppressing appetite through at least two routes. In the gut, he says it acts on enteric neurons in the automatic part of the nervous system and causes distension that makes a person feel full. Through a pathway running from the gut to the hypothalamus, he says it also triggers satiety in the brain. He expects the levels from yerba mate, or from appropriately dosed drugs, to cause mild distension, since he says major distension would be uncomfortable. He suggests yerba mate might suit people who want mild appetite suppression along with caffeine.
Huberman closes by widening the point. He says parallel pathways are fundamental to how the body is organized, and gives the example of adrenaline being released both from the adrenals and from the locus coeruleus in the brain. He adds that brain and body communication is almost always bidirectional. The clip is one person's explanation, and it names no specific drug brands or doses.
What this video doesn’t settle
- The clip summarizes one paper in Huberman's words and does not present the study's design, size or data.
- It does not name any specific GLP-1 drug, dose or trial result, so the clinical claims cannot be checked from the video.
- Huberman's suggestion that yerba mate may give mild appetite suppression is not backed in the clip by any measured effect size.
Questions this video answers
How does GLP-1 reduce appetite according to Huberman?
Huberman says the paper he discusses shows two routes. In the gut, GLP-1 acts on enteric neurons and causes distension that makes a person feel full. Through a pathway to the hypothalamus, he says it also triggers satiety in the brain.
What does Huberman say about yerba mate and GLP-1?
He says yerba mate can promote the release of GLP-1, but in a much lower amount than a drug that stimulates GLP-1 or a synthetic version of it. He says he avoids smoked varieties because of a potential carcinogenic concern.
What are parallel pathways in biology?
Huberman defines them as neural, hormonal or other pathways that operate independently of one another to reach a common goal. He gives adrenaline release from both the adrenals and the locus coeruleus as a second example.
What does Huberman say about the new GLP-1 drugs?
He says new prescription drugs that stimulate GLP-1 release, or are synthetic versions of it, have shown impressive clinical trials for diabetes and obesity. He describes them as leading to weight loss, and he does not name specific drugs or doses.
Video by Huberman Lab Clips on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
